Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 147 for “"Pharmaceutical companies."”.
-
The South African government, the pharmaceutical companies and access to HIV
Bibliography: leaves 67-82.
-
Technology acquisition strategies in pharmaceutical companies through equity investment, alliance and acquisition
The pharmaceutical industry is now confronted with a discontinuous time period, especially in terms of its technology. In order to maintain their advantageous positions in the industry, pharmaceutical companies have to invest not only in internal R&D but also in external sources, since technologies …
-
South Africa's national health reform : how leading R&D pharmaceutical companies are responding
… cost containment of the NHI will benefit generic companies whilst research and development (R&D) companies, the biggest upstream providers in the private healthcare sector in South Africa, might consider pulling out of the country. In order to ensure long-term sustainable growth within the new NHI …
-
How Pharmaceutical Companies Utilize Platform Strategy: A Study of the COVID-19 mRNA Vaccine Development
… and external factors from the perspective of a pharmaceutical company can be considered behind the rapid development of vaccines. However, this study focuses mainly on internal factors, especially from the perspective of platform theory from management perspectives. Platform theory has emerged …
-
Porter's strategy and the influence of guanxi and government policies in small and medium-sized pharmaceutical companies in China
… and implementation within small and medium-sized pharmaceutical companies (SMPCs). Given this business environment, the research reported here finds that the "pure form" of Porter's strategy theories do not work completely for China's pharmaceutical industry. In particular, two non-market factors …
-
Commercialization strategies of biotechnology companies
… to certain forms of collaboration with pharmaceutical companies to complete acquisitions of projects by the big pharmaceutical companies. In this thesis, we wanted to study commercialization strategies of several biotechnology companies. We wanted to investigate the rational for …
-
Science and technology driving change in drug R&D : some lessons for the Japanese pharmaceutical industry
… platform in the research and development of pharmaceutical drugs is changing dramatically -- from the traditional trial-and-error method to modem sophisticated methods that use Combinatorial Chemistry (CC), High Throughput Screening (HTS), and Gene Technology. Since the beginning of the …
-
Creating and capturing value in the biopharmaceutical sector
… ongoing implications of the realignment of the pharmaceutical industry knowledge base – from small molecule methods to new biomedical technologies – for the competitive positions of traditional pharmaceutical companies and biopharmaceutical start-ups. The theoretical approach draws on the modern …
-
Trends in Pharmaceutical Product Development 2000-2010
… the study was to find out, whether any trends in pharmaceutical product development could be detected from data on granted marketing authorisations. Also the lifecycle management approaches the major pharmaceutical companies use to protect their blockbuster products from generic competition and to …
-
Pharmaceutical R&D : an organizational design approach to enhancing productivity
The pharmaceutical industry is an $837 billion a year industry that is being plagued by low R&D productivity. This decline in productivity has resulted in significant erosion of value. From December 2000 to February 2008, the top 15 pharmaceutical companies lost about $850 billion in shareholder …
-
The Quality of Work Life: An Empirical Study
… the quality of work life in a selection of pharmaceutical companies in Egypt. It aims to test the relationships between the employees' perceptions of their quality of work life and; their perceptions of the degree of participation in decisionmaking available to them, their perceptions of …
-
Perspectives on Innovation Incentives on the EU Pharmaceutical Sector with Focus on EMA and Parallel Trade
… thesis examines the incentives for Originator Pharmaceutical Companies’ to innovate new medicinal products in the light of parallel trade and European Medicine Agency’s (“EMA”) access to documents policy. The topic is important because the society relies on innovation made by these …
-
Creation and capture of new uncontested market space: The case of pharmaceutical business in Tanzania
In a controlled industry, such as the pharmaceutical business where marketing communication is restricted by Act of Parliament, product or service differentiation strategies which include advertising are difficult to implement. Section 98 of the 2003 Tanzania Food, Drugs and Cosmetics Act imposes …
-
Financing ARV Drug Manufacture in Zimbabwe: Implications for technological capability upgrading and innovation for African local pharmaceutical production
… and professional discourses on local African pharmaceutical manufacture have concentrated on technology, technology transfer, economies of scale, human capital, and markets for drugs; neglecting the financing of working capital and capital investment and the role played by banks. When finance …
-
医疗化进程在中国男性肾病类广告中的体现 = Medicalization and Chinese TV advertisements for male kidney disorder drugs
… prescription drugs into nonprescription drugs, pharmaceutical companies make their products accessible to lay people without professional intervention. The thesis argues that this process of social medicalization, unlike the one described by Conrad which is dominated by medical professions, is …
-
An investigation of alliances between western life-science therapeutic and Indian firms
Large pharmaceutical companies (Multinational Pharmaceutical Companies or MPCs) have struggled in recent years with the rapidly accelerating costs of drug-discovery research and development. These costs continue to rise while resulting in fewer drug leads. Several industries have realized …
-
Redefining how pharmaceutical innovation gets done
… of research and development in the bio-pharmaceutical industry has been constantly declining since the early 2000's. One possible reason is that biomedical projects are risky, take a long time, and require significant investment. Hence, substantial capital has been shifted away from the …
-
External Network Manufacturing Capacity Design and Procurement in the Pharmaceutical Industry
Pharmaceutical companies typically manufactured therapeutic drugs internally; however, the increased rate of innovation in the last decade has significantly pushed the balance toward external manufacturing. Moreover, the consolidation of contract manufacturing organizations (CMOs) has generated a …
-
Assessing decision inputs in drug development between small, early stage companies and big pharma : is there is a difference?
… challenge facing large, publicly traded pharmaceutical companies, collectively referred to as "Big Pharma," is well known. The unprecedented success Big Pharma achieved over the past few decades in commercializing blockbuster products means that it is now faced with near-term patent …
Page 1 of 8